These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 17001181)

  • 1. Dose-escalated abarelix in androgen-independent prostate cancer: a phase I study.
    Beer TM; Ryan C; Bhat G; Garnick M;
    Anticancer Drugs; 2006 Oct; 17(9):1075-9. PubMed ID: 17001181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy.
    Beer TM; Garzotto M; Eilers KM; Lemmon D; Wersinger EM
    Urology; 2004 Feb; 63(2):342-7. PubMed ID: 14972486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy.
    Beer TM; Garzotto M; Eilers KM; Lemmon D
    J Urol; 2003 May; 169(5):1738-41. PubMed ID: 12686821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
    Garnick MB; Mottet N
    BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
    Tomera K; Gleason D; Gittelman M; Moseley W; Zinner N; Murdoch M; Menon M; Campion M; Garnick MB
    J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group.
    Garnick MB; Campion M
    Mol Urol; 2000; 4(3):275-7. PubMed ID: 11062384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer.
    Ozono S; Ueda T; Hoshi S; Yamaguchi A; Maeda H; Fukuyama Y; Takeda K; Ohashi Y; Tsukamoto T; Naito S; Akaza H
    Jpn J Clin Oncol; 2012 Jun; 42(6):477-84. PubMed ID: 22457321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer.
    McLeod D; Zinner N; Tomera K; Gleason D; Fotheringham N; Campion M; Garnick MB;
    Urology; 2001 Nov; 58(5):756-61. PubMed ID: 11711355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75.
    Wong SL; Lau DT; Baughman SA; Fotheringham N; Menchaca D; Garnick MB
    J Clin Pharmacol; 2004 May; 44(5):495-502. PubMed ID: 15102870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate cancer.
    Wagner M; Garzotto M; Lemmon D; Eilers KM; Beer TM
    Urology; 2005 Apr; 65(4):799. PubMed ID: 15833548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer.
    Debruyne F; Bhat G; Garnick MB
    Future Oncol; 2006 Dec; 2(6):677-96. PubMed ID: 17155895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer.
    de la Rosette J; Davis R; Frankel D; Kold Olesen T
    Int J Clin Pract; 2011 May; 65(5):559-66. PubMed ID: 21342376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer.
    Shore ND; Guerrero S; Sanahuja RM; Gambús G; Parente A
    Clin Ther; 2019 Mar; 41(3):412-425. PubMed ID: 30929678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormonal predictors of prostate cancer.
    Sofikerim M; Eskicorapci S; Oruç O; Ozen H
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer.
    Wong SL; Lau DT; Baughman SA; Menchaca D; Garnick MB
    Clin Pharmacol Ther; 2003 Apr; 73(4):304-11. PubMed ID: 12709720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.
    Crawford ED; Tombal B; Miller K; Boccon-Gibod L; Schröder F; Shore N; Moul JW; Jensen JK; Olesen TK; Persson BE
    J Urol; 2011 Sep; 186(3):889-97. PubMed ID: 21788033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists.
    Koch M; Steidle C; Brosman S; Centeno A; Gaylis F; Campion M; Garnick MB;
    Urology; 2003 Nov; 62(5):877-82. PubMed ID: 14624912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.